#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Precursor T-lymphoblastic lymphoma/leukaemia recurrent+1

Recruiting

InvestigationalNo placebo

Long-term Follow-up Study for Patients with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Treated with OC-1 Cells

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A

Contact Research Centre

Precursor T-lymphoblastic lymphoma/leukaemia recurrent+1

Recruiting

InvestigationalNo placebo

Study on the Safety and Effectiveness of OC-1 Therapy for Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A

Contact Research Centre

Precursor T-lymphoblastic lymphoma/leukaemia recurrent+4

Recruiting

Registered drugNo placebo

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Ruxolitinib

Contact Research Centre

Precursor T-lymphoblastic lymphoma/leukaemia recurrent+4

Recruiting

Registered drugNo placebo

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Trametinib

Contact Research Centre

Precursor T-lymphoblastic lymphoma/leukaemia recurrent+4

Recruiting

Registered drugNo placebo

Study of Dasatinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with MAPK/SRC Pathway Mutation

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Dasatinib

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.